DURATION OF THERAPY IN US PATIENTS TREATED FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) IN THE REAL-WORLD

被引：0
|
作者：
Romanus, D. [1 ]
Raju, A. [2 ]
Yong, C. [1 ]
Seal, B. [1 ]
Farrelly, E. [2 ]
Noga, S. [3 ]
Jhaveri, M. [1 ]
Labotka, R. [4 ]
Blazer, M. [5 ]
Parameswaran, H. [6 ]
机构：
[1] Millennium Pharmaceut Inc, Global Outcomes Res, Cambridge, MA USA
[2] Xcenda, Real World Evidence, Palm Harbor, FL USA
[3] US Med Affairs, Cambridge, MA USA
[4] Millennium Pharmaceut Inc, Oncol Clin Res, Cambridge, MA USA
[5] Xcenda, Global Hlth Econ & Outcomes Res, Palm Harbor, FL USA
[6] Med Coll Wisconsin, Dept Med, Milwaukee, WI 53226 USA
来源：
HAEMATOLOGICA | 2016年 / 101卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
E1301
引用
收藏
页码：538 / 539
页数：2
相关论文
共 50 条
  • [1] Real-World Evaluation of Teclistamab for the Treatment of Relapsed/Refractory Multiple Myeloma (RRMM)
    Asoori, Sireesha
    Popat, Rakesh
    Martinez-Lopez, Joaquin
    Kastritis, Efstathios
    Brunaldi, Larissa
    Bansal, Radhika
    Corraes, Andre De Menezes Silva
    Yong, Kwee
    Mactier, Catriona
    Corona, Magdalena
    Saez Marin, Adolfo Jesus
    Fotiou, Despina
    Dimopoulos, Meletios Athanasios
    Chhabra, Saurabh
    Ailawadhi, Sikander
    Parrondo, Ricardo
    Martin, Thomas
    Durie, Brian G. M.
    Lin, Yi
    BLOOD, 2023, 142
  • [2] Real-World Study of Treatment Patterns in Heavily Pretreated Relapsed/Refractory Multiple Myeloma (RRMM) in the US
    Wang, Peter Feng
    Sansbury, Leah
    DerSarkissian, Maral
    Ferrante, Shannon
    Bhak, Rachel
    Gorsh, Boris
    Zichlin, Miriam L.
    Yee, Christopher W.
    Boytsov, Natalie
    Khanal, Anamika
    Paka, Prani
    Noman, Ahmed
    Duh, Mei Sheng
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S423 - S423
  • [3] REAL-WORLD EXPERIENCE OF LENALIDOMIDE/DEXAMETHASONE TREATMENT FOR REFRACTORY/RELAPSED MULTIPLE MYELOMA (RRMM) PATIENTS
    Tognazzi, L.
    Rivolti, E.
    Quaresima, M.
    Labbozzetta, S.
    Gamberi, B.
    Merli, F.
    HAEMATOLOGICA, 2017, 102 : 137 - 137
  • [4] Bortezomib therapy in a real-world setting in patients with relapsed or refractory multiple myeloma
    Huang, Shang-Yi
    Chen, Tsai-Yun
    Kuo, Ching-Yuan
    Chen, Yeu-Chin
    Lin, Sheng-Fung
    Chang, Ming-Chih
    Lv, Xinzhu
    Yang, Betty
    Chang, Cheng-Shyong
    ONCOLOGY REVIEWS, 2019, 13 (01) : 15 - 22
  • [5] Therapy of relapsed and/or refractory multiple myeloma (RRMM)
    Engelhardt, M.
    Waesch, R.
    ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 : 14 - 14
  • [6] Belantamab Mafodotin (Belamaf) for Relapsed/Refractory Multiple Myeloma (RRMM): A Real-World Observational Study
    Hultcrantz, Malin
    Kleinman, David
    Vij, Ravi
    Escalante, Fernando
    Kotowsky, Nirali
    Bitetti, Jacopo
    Mackay, Christine
    Boytsov, Natalie
    Camadoo-O'Byrne, Leena
    Germain, Guillaume
    Duh, Mei Sheng
    Laliberte, Francois
    Mahendran, Malena
    Urosevic, Ana
    Lee, Hans C.
    BLOOD, 2022, 140 : 10124 - 10126
  • [7] Carfilzomib Prescribing Patterns and Outcomes for Relapsed or Refractory Multiple Myeloma (RRMM): A Real-World Analysis
    Dong, Sharlene
    Banerjee, Rahul
    Khan, Adeel
    Wang, Mengru
    Wang, Xiaoliang
    Afghahi, Anosheh
    Afrough, Aimaz
    Janakiram, Murali
    Wang, Bo
    Cowan, Andrew
    Sperling, Adam
    Anderson, Larry
    Rajkumar, S. Vincent
    Kaur, Gurbakhash
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S258 - S259
  • [8] Real-world Effectiveness of Ixazomib, Lenalidomide, and Dexamethasone (IRd) in Asian Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
    Moon, Joon-Ho
    Ng, Soo Chin
    Park, Sung Soo
    Koh, Youngil
    Lee, Ji Hyun
    Eom, Hyeon-Seok
    Shin, Ho-Jin
    Lee, Je-Jung
    Do, Young Rok
    Wilfred, Gilbert
    Husin, Azlan
    Kim, Hyo Jung
    Wahid, S. Fadilah Abdul
    Lee, Myung-Won
    Heo, Hye-won
    Kim, Kihyun
    Chuncharunee, Suporn
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S263 - S264
  • [9] Real-World and Clinical Trial Data in Relapsed/Refractory Multiple Myeloma (RRMM): Evaluating Treatment Duration and Comparing Effectiveness and Efficacy
    Richardson, Paul G.
    San Miguel, Jesus F.
    Moreau, Philippe
    Hajek, Roman
    Dimopoulos, Meletios A.
    Palumbo, Antonio
    Luptakova, Katarina
    Skacel, Tomas
    Kumar, Shaji K.
    Anderson, Kenneth C.
    BLOOD, 2017, 130
  • [10] Relationship of Carfilzomib Dosing and Duration of Therapy (DOT) in Patients with Relapsed and Refractory Multiple Myeloma (RRMM)
    Harvey, R. Donald
    Chen, Yaozhu J.
    Lethen, Jan
    Mahue, Maya
    BLOOD, 2015, 126 (23)
12345